Does estrogen play a role in response to adjuvant bone-targeted therapies?

Results of subgroup analyses demonstrated a significant reduction in bone metastases at two-years ( P =0.017) and a trend towards significance at five-years ( P =0.056) in postmenopausal patients treated with two years of adjuvant clodronate therapy versus the premenopausal subgroup, which showed no benefit with clodronate on the risk of bone metastases either at two-years ( P =0.448) or five-years ( P =0.334). 7.2 AZURE The AZURE trial, although a negative study overall, did show benefit with adjuvant BP therapy in women who had been in menopause for at least five years [5] .

also in 2,760 other papers

A follow-up biomarker analysis using serum collected and stored on 872 AZURE patients for use in future translational research showed a trend towards benefit with the use of ZA in biochemically postmenopausal women [65] .

also in 53,322 other papers